Takeda

In 2003, Takeda acquired the rights for development and commercialisation of CAMETOR® (cetilistat) known as OBLEAN® in Japan from Alizyme. The product is used to treat obesity. In 2009, all CAMETOR® rights were acquired by Norgine.

In 2011, Norgine out-licensed MOVIPREP® rights to Nycomed, now Takeda for Russia/CIS.